From product conception to commercialization, each stage in the lifecycle of a medical device, pharmaceutical or commercial product can be extremely challenging especially when sterilization is a required outcome. To enhance your knowledge and optimize results, take part in this exclusive three-day seminar on topics critical to achieving sterility assurance.

Industry experts will provide attendees with a greater understanding of the association between sterilization, lab testing, product, packaging and validation as well as relevant ISO regulations. Coursework includes real-life case studies and hands-on demonstrations.

SEMINAR TOPICS INCLUDE

  • Radiation

- Introduction to irradiator technology 
(Gamma, E-Beam, X-Ray) and radiation        sterilization terminology
- Establishing sterilization dose
- Establishing maximum acceptable dose
- Process validation (IQ/OQ/PQ)

  • Ethylene Oxide (EO)

- Introduction to EO processing
- How to develop, validate and 
requalify a successful EO sterilization process
- Product design and packaging considerations
- EO cycle optimization 
- Parametric release for EO sterilization

  • Sterilization microbiology & lab testing Presented by Nelson Labs Global leader in lab testing and expert advisory services
  • Medical Device Regulation (MDR) compliance update

NETWORKING RECEPTION:

Join us on Day 1 for an evening networking reception. Sterigenics and Nelson Labs Expert Advisors will be available for informal one-to-one discussions.

REGISTRATION:

890 € 

early bird for registrations by 15 january 

890 € 

for 2 or more participants from the same organization

1 150 € 

for registrations after 15 January

Certificate of course completion will be made available for all attendees.

Registration includes attendance for the seminar, meals (lunch, and refreshments). Please note: registration does not include hotel accommodations.

SEMINAR LOCATION AND HOTEL ACCOMMODATIONS:

Mercure Chantilly Resort & Conventions, Route d’Apremont 60500 Vineuil-Saint-Firmin, France
www.mercure-chantilly.com

Mercure Chantilly Resort & Conventions, is a 4 star hotel and welcome destination in the heart of the historic Chantilly forest. It is located just 40 minutes from Paris, 25 minutes from the Charles de Gaulle International Airport and 25 minutes by Thalys train from Gare du Nord to Chantilly-Gouvieux.

Attendees planning to stay at the hotel can take advantage of the discounted bed and breakfast rate of 150 ° per night. To make your reservation, please call the hotel reservation center at +33 3 44 58 47 77 and request the Sterigenics group rate. Discounted rooms are available on a limited basis. 

FOR MORE INFORMATION 

Visit our website: sterigenics.com

Email: Amie Casson with any questions aecasson@sterigenics.com

About Sterigenics

We are over 1600 engineers, scientists, safety specialists and solution providers focused on eliminating threats to the health of humanity and providing comprehensive sterilization solutions. We have global breadth and more than 90 years of deep expertise across Gamma, Ethylene Oxide, E-Beam and X-Ray sterilization. Our operations span 45 facilities in 13 countries to ensure we are the “point of safe” for our customers.

Safeguarding Global Health® - with every product we sterilize.

Go to article: Home | The power of patientsGo to article: Scandinavian Health Company InsightGo to article: Scandinavian Health Ltd.Go to article: In this issueGo to article: NSFGo to article: ContentsGo to article: CapsugelGo to article: Capsugel Company Insight Go to article: Christensella: the key to unlocking gut microbiome-based drug discovery?Go to article: Molnar Company InsightGo to article: Molnar-InstituteGo to article: A costly oversight: the ongoing impact of the valsartan recallGo to article: Novo Nordisk Company InsightGo to article: Novo NordiskGo to article: Where is the UK’s supply of Migraleve?Go to article: Dupont PharmaceuticalsGo to article: Discussing drug policy reform with psychedelics campaigner Amanda FeildingGo to article: LB Bohle Company Insight Go to article: LB BohleGo to article: Charting the life and times of the EMA as it leaves LondonGo to article: Komtur Pharmaceuticals Company InsightGo to article: Komtur PharmaceuticalsGo to article: CBD: the myth, the magic and the real deal drugsGo to article: CBDepot Company InsightGo to article: CBDepotGo to article: In the age of AMR, does a nationalised drug company make sense? The case for and againstGo to article: AtoZ-CRO Company InsightGo to article: AtoZ-CROGo to article: How do cancer cells communicate and can it help us catch them?Go to article: HOF SonderanlagenbauGo to article: HOF Sonderanlagenbau Company Insight Go to article: Buyers’ clubs: the first step toward universal UK access to Orkambi?Go to article: SterigenicsGo to article: Owen MumfordGo to article: Are we nearing the end of animal testing in pharma?Go to article: Zenatek Go to article: Barc Lab Go to article: A safer ride: the latest innovation in targeted cancer treatment Go to article: Abiogen PharmaGo to article: MimotopesGo to article: Next issue